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Thrombotic risk assessment in antiphospholipid 
syndrome: the role of new antibody specificities 
and thrombin generation assay 
Savino Sciascia, Simone Baldovino, Karen Schreiber, Laura Solfietti, Massimo Radin, 
Maria J. Cuadrado, Elisa Menegatti, Doruk Erkan and Dario Roccatello 
Abstract 
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the presence of 
antiphospholipid antibodies (aPL) in subjects presenting with thrombosis and/or pregnancy loss. 
The currently used classification criteria were updated in the international consensus held in Sidney 
in 2005. Vascular events seem to result of local procoagulative alterations upon triggers influence 
(the so called “second-hit theory”), while placental thrombosis and complement activation seem to 
lead to pregnancy morbidity. The laboratory tests suggested by the current classification criteria 
include lupus anticoagulant, a functional coagulation assay, and anticardiolipin and anti-β2-
glycoprotein-I antibodies, generally detected by solid phase enzyme-linked immunosorbent assay. 
The real challenge for treating physicians is understanding what is the actual weight of aPL in 
provoking clinical manifestations in each case. As thrombosis has a multi-factorial cause, each 
patient needs a risk-stratified approach. In this review we discuss the role of thrombotic risk 
assessment in primary and secondary prevention of venous and arterial thromboembolic disease in 
patients with APS, focusing on new antibody specificities, available risk scoring models and new 
coagulation assays 
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Background 
The strive for personalised medicine can be traced in its origin to Hippocrates’ times: the 
assessment of the four humours—blood, phlegm, yellow bile and black bile—were essential to 
determine the correct treatment for each individual patient. Nowadays, the emphasis on disease 
prediction and prevention remains the main hallmark and challenge of individualised and 
personalised medicine and is largely dependent on advances in research and published literature. 
One of the most ubiquitous examples to personalise medicine is the development of risk 
stratification or scoring models in order to predict the development of any given clinical outcome or 
disease.The eagerness to develop and validate reliable scoring models for the prediction of clinical 
outcomes in order to improve individual clinical care has motivated researchers within the field of 
autoimmune diseases to propose useful scoring models [1, 2, 3, 4]. Especially in areas with a variety 
of clinical effectors and outcome variables, solid scoring systems are essential to provide a valuable 
guidance in clinical practice to advise clinicians to the right treatment strategy. 
The antiphospholipid syndrome (APS) is a systemic autoimmune disease, which is defined by the 
presence of thromboses and/or obstetric morbidity in patients persistently positive for 
antiphospholipid antibodies (aPL). The classification criteria for APS have been outlined in the 
original Sapporo criteria, and have more recently been updated in the Sydney criteria [5] (Table 1). 
aPL comprehends a heterogeneous group of circulating immunoglobulins including lupus 
anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-β2glycoprotein-I (anti-β2GPI). Their 
persistent presence is related to diverse clinical phenomena including arterial and venous 
thrombosis, pregnancy complications and other common clinical manifestations such as livedo 
reticularis or thrombocytopenia. As the presence of aPL does not always lead to thrombotic events 
in every individual with aPL, aPL are necessary, but not sufficient for clinical manifestations such 
as thromboembolic events or pregnancy morbidity. A “second hit theory” has been proposed, 
suggesting that other factors may trigger a clinical manifestation in individuals with aPL [6, 7]. 
Shi et al. studied the prevalence of LA and aCL in 499 healthy Australian blood donors and found 
LA to have a prevalence of 3.6 % and aCL, 4.6 % [8], whereas 1 % of healthy control patients in 
the Leiden Thrombophilia study were found to have LA and 3.6 %, anti- β2GPI antibodies [9]. The 
prevalence of aPL is higher in patients with other autoimmune conditions such as rheumatoid 
arthritis or systemic lupus erythematosus (SLE), where up to 40 % are persistently positive for aPL 
[10, 11]. Given their heterogeneity, their combinations and titres researchers have focused on 
exploring their link to different risks of clinical outcomes [12, 13, 14, 15]. Furthermore, scoring 
models for the use in aPL positive individuals and patients with APS to predict the risk of 
thrombosis have been developed and validated by different groups [1, 2, 16, 17]. 
In this review we discuss the role of thrombotic risk assessment for venous and arterial 
thromboembolic disease in aPL-positive patients, focusing on new antibodies specificities, available 
risk scoring models and new coagulation assays. A comprehensive analysis of the therapeutic 
options for the management of aPL-positive patients is beyond the scope of this review; detailed 
information about current and potential future management strategies can be found elsewhere [6]. 
Clinical manifestations of APS 
APS is widely considered as the major acquired thrombophilia, which can affect any vascular bed 
(arterial, venous and the microvasculature). This may explain the variety of clinical manifestations 
described in APS patients. Albeit most of the clinical manifestations can be attributed to underlying 
thrombosis, inflammation, complement, platelet activation and macrophages have been shown to 
play crucial roles in the pathophysiology of the syndrome [6]. 
In a European cohort of 1000 APS patients, deep vein thrombosis (DVT) and pulmonary embolism 
(PE) were the most frequent clinical manifestations of the syndrome, whereas the most frequent 
arterial manifestations are neurological, such as stroke or transient ischemic attacks (TIA) [18]. 
Other neurological features include migraine headaches, memory loss and epilepsy. 
Thrombocytopenia and livedo reticularis are the most important haematological and dermatological 
characteristics, respectively, and can be found in up to 20 % of APS patients [18]. Pregnancy 
morbidity includes unexplained fetal death, premature birth before 34 weeks of gestation due to 
severe pre-eclampsia, eclampsia or placental insufficiency or recurrent first trimester miscarriage. 
Pre-eclampsia, premature birth or fetal loss are the most common manifestations and occur in 10–
20 % of APS pregnancies [18]. 
Laboratory testing for aPL 
aPL can be detected with three tests, all of which should be performed in any individual patient 
before the presence of aPL can be excluded or confirmed. The assays comprise test for the presence 
of lupus anticoagulant, anticardiolipin antibodies and anti-β2GPI [19, 20]. Individuals may be 
positive for one, two or three of these tests and are in the literature referred to as single, double or 
triple positive, respectively. 
 
Lupus anticoagulant testing 
LA is a functional assay measuring the ability of aPL to prolong phospholipid—dependent clotting 
assays. LA testing has been difficult to standardise, and no single test appears to be adequate, 
indicating the heterogeneity of different individuals aPL. As no coagulation test has 100 % 
sensitivity, the 2009 Scientific and Standardisation Committee of the International Society on 
Thrombosis and haemostasis guidelines recommend two assays of different assay principle, the 
diluted Russell viper venom (dRVVT) test and a sensitive activated partial thromboplastin time 
(aPTT), with silica as an activator because of its sensitivity for LA [19]. According to the updated 
guidelines, the laboratory detection of LA should be based on the following criteria: (1) 
prolongation of phospholipid dependent clotting test, in particular when the phospholipid content of 
test system is low; (2) lack of correction of the prolonged clotting time by addition of a small 
amount of normal plasma (thereby to exclude factors deficiency); (3) correction by the presence of 
high concentration of phospholipid such as the use of platelet fragments, which will remove all the 
aPL, or by the use of a reagent that is poorly responsive for LA effect [19]. Similarly, current 
guidelines for LA detection recommend mixing test interpretation with either a mixing test-specific 
cut-off (MTC) or index of circulating anticoagulant (ICA) [19]. Very recently, Moore et al. [21] 
retrospectively applied MTC and ICA assessment to raw data of 350 LA positive plasmas from 
non-anticoagulated patients to compare detection rates of inhibition. They concluded that it is 
valuable to maximise mixing test interpretation as the dilution can lead to false negative results. 
Consequently, MTC is superior to ICA in detecting the in vitro inhibition of LA and might be a 
useful tool when assessing the risk in patients suspected for APS. 
 
Anticardiolipin antibodies.  
aCL are usually detected by either radioimmunoassay or ELISA, using cardiolipin as the solid 
phase antigen. Serum is used for the aCL assays. IgG, IgM and/or IgA isotypes concentrations are 
expressed as GPL, MPL and/or IgA units, respectively, where 1 unit represents the binding activity 
of 1 mg/ml of affinity purified aCL antibody. aCL IgG and IgM are currently part of the APS 
classification criteria [5], whereas the clinical value of aCL IgA remains subject of discussion as 
outlined below. In general, positive LA tests are more specific for the APS, whereas aCL are more 
sensitive [9, 17]. The specificity of aCL for APS increases with the titre and is higher for the IgG 
than for the IgM isotype. However, some patients may have only a positive IgM test, and a few are 
only IgA positive. 
 
Anti-β2glycoprotein-I and anti-domain I-β2glycoprotein-I antibodies 
The development of anti-β2GPI immunoassays followed the observation that many aCL are 
directed to an epitope on β2-glycoprotein. However, in patients with clinical features of APS, anti-
β2GPI antibodies are rarely the sole antibodies detected [15]. 
The β2GPI has five homologous domains (D1 to D5) and recently several studies focused their 
attention on the epitope distribution of anti-β2GPI antibodies, in order to identify the pathogenic 
specificities [22]. The main epitope that has been found to be associated with APS involves regions 
of D1 [23]. Recent promising data support the association between anti-β2GPI-D1 and APS clinical 
manifestation. Recent studies have found that patients with multiple aPL have a higher prevalence 
and higher titers of anti-β2GPI-D1 antibodies [22, 23]. International multi-centre evaluations have 
recently confirmed the preliminary reports supporting the associations between an history of 
thrombosis (mostly venous) and anti-β2GPI-D1 antibodies (reviewed in [24]). Taken the above 
together, anti-β2GPI-D1 antibodies might be a promising biomarker for risk assessment in APS. 
Further studies are warranted to validate this hypothesis. 
 
IgA aPL isotypes 
To date, no conclusive prospective study has offered a clear view on the usefulness of IgA aPL 
antibodies testing. IgA aPL antibodies have a low prevalence and in most cases they are found 
along with other aPL, but they have failed to enhance the diagnostic accuracy when routinely tested 
[25]. 
To date, the use of IgA isotypes for both aCL and anti-β2GPI are not a part of the routine diagnostic 
algorithm [20]. However some data suggested a role of isolated positivity for IgA anti-β2GPI with 
clinical APS symptoms might help to identify additional patients, recommending this tests when 
other aPL are negative. Based on the present evidence IgA aPL testing should be considered for 
thrombotic assessment risk only in selected patients, in particular when other aPL tests are negative, 
in the presence of clinical APS signs and/or symptoms, mainly associated with SLE [20]. 
Non criteria aPL 
Antiprothrombin antibodies 
The role of aPL assays for the detection of autoantibodies to phospholipids other than criteria 
antiphospholipid antibodies (for example anti-prothrombin or anti-phosphatidylserine) is an 
ongoing subject of debate. These antibodies are directed to negatively charged phospholipids other 
then cardiolipin. Specifically, antibodies to prothrombin can be detected by directly coating 
prothrombin on irradiated ELISA plates (aPT) or by using the phosphatidylserine/prothrombin 
complex as antigen (aPS/PT) [26]. Although these antibodies can co-exist in the same patient, they 
are two distinct populations of antibodies. In fact, aPS/PT (rather than aPT) has been shown to help 
to establish the diagnosis of APS and the associated risk for both arterial and/or venous thrombosis 
or pregnancy morbidity [27]. Their clinical importance is far from being fully explored, but the 
presence of these other aPL antibodies might represent a new tool for risk stratification, especially 
for those patients negative for the classic aPL. 
 
Anti-phosphatidylethanolamine antibody 
In solid assays, sera from patients with APS usually react to negatively charged phospholipids (PL) 
and PL cofactors such as β2-glycoprotein I (β2GPI). Binding to non negative charged PL (such as 
neutral PL, e.g. phosphatidylethanolamine) is less frequently observed [28]. 
Phosphatidylethanolamine (PE) is one of the main lipid components of the cell membranes, being 
mostly located in the inner leaflet [28]. In 1989 Staub et al. [28] reported the first case of primary 
APS whereby a LA was accompanied not by an aCL, but by an antibody to PE (aPE). 
The clinical significance of aPE in patients with the thrombosis and/or pregnancy morbidity but 
negative for criteria aPL (so-called seronegative APS) is a very hot topic under investigation. 
Hirmerova et al. [29] showed that in 140 patients with venous thromboembolism, of non-criteria 
aPL antibodies, only aPE was significantly more prevalent compared to controls, with minor 
overlapping with the criteria aPL. Moreover, aPE antibodies were associated with a higher risk of 
thrombosis in a multicentre study including 270 patients with thrombotic disease and 236 matched 
controls [30]. Of note, more than 60 % of 40 aPE-positive patients were negative for the APS 
laboratory criteria. Similar results were found by the same group [31]. The screening for IgG, IgM 
and IgA aPE, seems to increase the diagnostic yield in APS [32], particularly when traditional 
laboratory criteria for APS are lacking [33]. After more than 25 years from the first description of 
aPE antibodies in a patient with primary APS [34], the clinical value of these antibodies in 
individuals with unexplained thrombosis and pregnancy morbidity remains intriguing. Whilst solid 
evidence supporting the inclusion of aPE as classification criteria for APS is lacking, one may 
consider testing for aPE in patients with clinical features suggestive of APS without the presence of 
criteria aPL [35]. 
 
Anti-vimentin antibodies 
Vimentin is a ubiquitous protein part of the cytoskeleton intermediate filament structure. Anti-
vimentin antibodies were first described in patients with SLE, and they reportedly exhibit 
significant association with the presence of aCL [36]. Albeit anti-vimentin antibodies have been 
shown to activate platelets and leukocytes with increased expression of P-selectin, fibrinogen, TF, 
and platelet-leukocyte conjugates [37], the diagnostic role of in the context of APS is still largely 
undefined. Ortona et al. [38] demonstrated that vimentin is capable of binding cardiolipin in vitro, 
possibly as a result of electrostatic interaction between its positively charged amino acids and the 
negatively charged amino acids of cardiolipin. The antivimentin/cardiolipin antibody complexes 
were found in a large proportion of patients with clinical features suggestive of APS without criteria 
aPL patients tested and almost all those with APS [38]. These findings led the authors to consider 
vimentin as a new antigenic cofactor for aPL in APS and the vimentin/cardiolipin complex as a 
molecular target of the antibodies in APS patients. It is important to note, however, that 
antivimentin/cardiolipin antibodies also have been detected in SLE and RA patients, so despite their 
high sensitivity, these antibodies are not very specific for APS. 
 
Anti- annexin A5 and anti-annexin 2 antibodies 
Anti-AnxA5 antibodies (aAnxA5) have also been described in APS. Despite promising results 
observed in mice where aAnxA5 have been associated with placental thrombosis and fetal 
absorption [39], conflicting findings have been observed concerning the association of aAnxA5 
with a history of pregnancy-related morbidity in humans [40, 41, 42]. Similarly, de Laat et al. [43] 
did not observe any association between aAnxA5 and a history of thrombosis. 
Annexin 2 is a cofactor for plasmin generation and cell-surface localization of fibrinolytic activity, 
(mainly monocytes, placental syncytiotrophoblasts and endothelialium) [44, 45]. Cesarman-Maus et 
al. were the first to describe the high prevalence of anti-annexin 2 antibodies in patients with APS 
[46]. Several observations might be in line with a pathogenic role for anti-annexin 2 antibodies in 
APS (e.g. induction of TF expression on endothelial cells; second, prevention of placental annexin 2 
from acting as a cofactor during plasmin generation) [39]. However, their clinical relevance remains 
a matter of debate and needs to be confirmed with experimental data as well as longitudinal studies 
involving sufficient number of patients. 
 
Thrombin generation assay and APS 
A significant number of studies highlight that an altered thrombin generation may lead to pathologic 
processes, meanly haemorrhagic or thrombotic diseases [47]. Recent tests based on the continuous 
detection of thrombin generation under in vitro conditions that mimic more closely what occurs in 
vivo, has motivated a reinvestigation of the balance between pro-coagulants and anti-coagulants in 
patients with various haemostatic disorders. Furthermore, the evaluation of an individual’s 
thrombin-generation potential serves as a useful estimator of the total coagulation potential, i.e. 
hyper- or hypocoagulability, when compared to traditional coagulation tests [48]. The clinical utility 
of thrombin generation tests however remains subject to highly specialised teams and is far from 
being used in standard clinical practice. However, TGA (thrombin generation assay) is a simple and 
reproducible technique that potentially can be used in coagulation laboratories. The test measures 
the amount of thrombin formed immediately after citrated plasma recalcification by adding 
exogenous activators (human recombinant tissue factors (TF) and phospholipids). Concentration of 
generated thrombin in the sample is recorded and then calculated from the fluorescence over time 
variation of the substrate, resulting in a thrombin generation curve. The following parameters are 
acquired: Lag time (tLag, time until thrombin burst), time to Peak thrombin generation (tPeak), 
peak amount of thrombin generation (Peak), velocity of thrombin generation (vel), and the total 
amount of thrombin generated (AUC, Area Under the thrombin generation Curve) [49]. 
The clinical utility of TGAs in assessing the thrombotic risk has been a matter of growing interest 
[47]. However, to date, TGA has been applied only for research purpose and its role in clinical 
practice still needs to be evaluated. 
Few studies [50, 51, 52, 53] described an association between an unbalance in TGA parameters and 
thrombotic risk in APS. Dienava-Verdoold et al. [50] showed successful cloning of patient-derived 
mAbs that require domain I of β2GPI for binding, and that display LA activity that is dependent on 
their affinity for β2GPI. When assessing the thrombin generation by using calibrated automated 
thrombography, it has been shown that lag time is influenced by the presence of anti-β2GPI 
antibodies, and that the prolongation of the lag time was similar to the clotting time prolongation 
observed in the dRVVT and the aPTT assay. 
Regnault et al. applied the thrombinography assessed by the conversion of a fluorogenic substrate in 
order to investigate the presence of acquired resistance to activated protein C (APC) in patients with 
LA [51]. They observed the complete process of thrombin formation and decay and its delimitation 
by the protein C system in eight consecutive LA-patients (all patients were not taking 
anticoagulation therapy). In 7 out of 8 patients they observed a long lag-time before the thrombin 
burst (LA effect) together with a marked inability of APC to diminish the thrombin activity. The 
lag-phase was however prolonged to some degree by APC when compared to controls. The effects 
were more evident in the presence of phospholipids from patients’ platelets than with added 
phospholipids. Thus, thrombinography demonstrates APC resistance in LA-patients despite the 
occurrence of long lag-times (clotting times). 
These observations were confirmed by Zuily et al. [53] when they studied acquired APC resistance 
in patients with aPL using a TGA. A parameter summarizing APC inhibition of thrombin 
generation with increasing APC concentrations (IC(50)-APC) was increased in all patient groups 
compared to controls: median values were 15.3 (interquartile range, IQR, 9.7–34.0) in patients with 
primary APS, 27.3 (IQR 23.5–43.5) in patients with SLE without APS, 64.1 (IQR 25.9–65.0) in 
patients with SLE/APS compared to 10.4 [IQR 8.5–15.8] in controls, respectively p = 0.003, 
p = 0.0001 and p = 0.0001. 
More recently, Efthymiou et al. [52] compared the degree of anticoagulation intensity in thrombotic 
APS and non-APS patients (50 in each group) on long-term warfarin. The group measured the INR 
with two widely available thromboplastins with instrument-specific ISI values in order to 
investigate the potential role of amidolytic FX levels and thrombin generation. While there were no 
overall differences in INR between reagents or patient groups. 
ETP and peak thrombin showed significant inverse correlations with the INR, suggesting that TGA 
testing may be helpful in the determination of true anticoagulant intensity in APS patients, 
including those with ≥3.5 INR. Thrombin generation testing also highlighted a subgroup of APS 
patients with increased peak thrombin relative to the intensity of anticoagulation as assessed by INR 
and FX, supporting thrombin generation testing as a possible tool for the identification of ongoing 
prothrombotic states in patients on warfarin. 
Overall, TGA seems a promising tool to further asses the thrombotic risk in patients with aPL; 
besides, TG testing may be useful in identifying subgroups of patients at higher risk such as those 
with an ongoing prothrombotic state and apparently adequate anticoagulation intensity as assessed 
by INR. 
 
Thrombotic risk assessment in aPL carriers and APS 
aPL titres as well as their single, double or triple presence, have all been suggested to have a 
different distinct clinical significance [12, 13, 15, 17]. 
In general, the presence of aPL in individuals without any clinical manifestations, i.e. aPL carriers, 
can generally been seen as a risk factor for first time thromboembolic events [12]. LA has been 
shown to be a better predictor for thrombosis compared to any other aPL. In details, in 2003 Galli et 
al. showed in a systematic review that LA is a strong risk factors for both arterial and venous 
thrombosis. The group assessed the risk of thrombosis associated with LA and aCL on studies 
including 753 patients and 234 controls and found a significant relation between LA and thrombosis 
with an OR ranging from 5.7 to 9.4 aCL in turn was never associated with arterial or venous 
thrombotic events [54]. Of note, when the systematic review was performed, anti-β2GPI were 
routinely tested and the studies were performed prior to the latest amendment of the APS 
classification criteria where anti-β2GPI was included into the criteria. 
Conversely, De Groot et al. showed in their Leiden cohort, that the presence of LA alone without 
the presence of anti-β2GPI (or antiprothrombin antibodies) was not significantly associated with a 
risk for a first DVT (OR 1.3, 95 % CI 0.3–6.0). However, in patients who tested positive for LA and 
anti-β2GPI antibodies (or anti-prothrombin) the OR of a first time deep venous thrombosis 
increased to 10.1 (95 % CI 1.3–79.8) [9]. 
More recently, Pengo et al. showed that the presence of triple positive patients carries a higher risk 
of thrombosis (and adverse pregnancy outcome) compared to patients with positivity for only one 
aPL. The risk associated to the so-called ‘triple positivity’ (defined as the simultaneous positivity 
for LA, aCL and anti-β2GPI) was assessed in a study describing clinical outcomes of one hundred 
thirty-three patients after 1 year follow-up, 76 patient after 5 year follow-up and 23 patients after 
10 year follow-up. Over 30 % had a thromboembolic event during their follow up. Interestingly, 
there were more arterial events compared to venous events (25 had a venous thromboembolic event 
and 30 patients experienced an arterial event). However, it is worth noting that compliance with 
regards to anticoagulation therapy was not specified [55]. 
Otomo et al. expanded on this principle and developed the aPL-score (aPL-s), with the aim to 
evaluate whether aPL titres influence the risk of thrombosis, comparing high to medium/low titres 
of aCL and anti-β2GPI IgG and IgM, respectively. The group showed that high levels of IgG aCL, 
anti-β2GPI (and also anti-phosphatidylserine and anti-prothrombin antibodies) were closely related 
to the clinical manifestations of APS. In their study the aPL-score related with a history of 
thrombosis or pregnancy morbidity. Moreover, the aPL-s score was shown to be of predictive value 
for the recurrence and/or new onset of thrombotic events [1]. These preliminary observations were 
independently validated [16]. 
Moving towards the concept of aPL as a risk factor, our group recently published a comprehensive 
series of studies developing and validating the global APS score (GAPSS) in different patients 
populations [2]. The GAPPS score combines independent risk factors for thrombosis and pregnancy 
loss, taking into account aPL profiles (criteria aPL and non criteria aPL), as well as conventional 
cardiovascular risk factors and autoimmune antibody profiles. 
Among all the computed variables (extensive aPL testing, cardiovascular risk factors evaluation, 
autoimmune profile), multivariate logistic regression analysis showed that only arterial 
hypertension, hyperlipidaemia, LA, aCL IgG and/or IgM, anti-β2GPI IgG and/or IgM and aPS/PT 
IgG and/or IgM were independent risk factors for thrombosis and/or pregnancy morbidity. All 
variables were computed as dichotomized, in order make GAPSS more widely adoptable. aPL 
positivity was assessed according to the updated APS classification criteria [5]. 
The GAPSS includes IgG/IgM aCL (five points), IgG/IgM anti-β2GPI (four points), LA (four 
points), IgG/IgM anti-phosphatidylserine-prothrombin complex antibodies (three points), 
hyperlipedaemia (three points) and arterial hypertension (one point) (Table 2). 
 
The GAPSS model was developed in patients with systemic lupus erythematosus (SLE) and higher 
GAPS scores were observed in patients who experienced thrombosis and/or pregnancy loss 
compared with those without clinical events. Moreover, the GAPSS score was evaluated in an other 
prospective study of 51 SLE patients [56] and in 62 consecutive patients with primary APS (PAPS) 
[3]. In both cohorts an increase in the GAPSS was found in patients who experienced thrombosis 
during the follow up period compared with those without events. Furthermore, higher GAPSS 
scores were observed in patients who experienced thrombosis compared with those with pregnancy 
morbidity alone. In more detail, patients with GAPSS values higher or equal of 11 were shown to 
have a higher risk of recurrences. 
The GAPSS model was further applied and validated by two independent groups. Oku et al. [57] 
described, in a large cohort of rheumatologic patients, that APS manifestations (thrombosis or 
pregnancy morbidity) were experienced by patients with higher GAPSS values compared to patients 
without APS manifestations. Recently, in another large cohort with APS and SLE patients, Zuily et 
al. described mean GAPSS values significantly higher for patients who underwent a thrombotic 
event compared to those who didn’t experienced a thrombotic event [53]. 
Conclusions and future research agenda 
An individual thrombotic risk assessment and “risk stratification” are fundamental for good clinical 
practice when evaluating patients with persistent aPL. Currently, this assessment is mostly limited 
to traditional cardiovascular and venous risk factors as well as aPL (LA test, aCL, and anti-β2GPI) 
profile. However, the field is moving towards better “risk stratification” given that new aPL tests, 
biologic risk assessment, e.g., thrombin generation, and aPL-specific thrombosis risk calculators 
have been studied in aPL-positive patients. Thus, future research agenda is promising and requires 
international collaboration. 
AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal networking (APS 
ACTION) is the first-ever international research network that has been created specifically to 
design and conduct well-designed, large-scale, multicenter clinical studies in persistently aPL-
positive patients. 
Among other activities [58, 59, 60, 61], in early 2012, APS ACTION launched an international 
clinical database and repository “registry” of persistently aPL-positive patients with or without 
systemic autoimmune diseases, which also includes annual blood collection for aPL-testing and 
future basic science studies. To date, the network is composed of 49 multidisciplinary physicians 
and investigators interested in APS research from 29 international centers (www.apsaction.org). We 
believe that collaborative efforts such as APS ACTION will help better define thrombosis risk 
assessment in APS. 
 
Abbreviations 
APS: antiphospholipid syndrome 
 aPL: antiphospholipid antibodies 
 TGA: thrombin generation assay 
LA: lupus anticoagulant 
 aCL: anticardiolipin antibodies 
 SLE: systemic lupus erythematosus 
Anti-β2GPI: anti-β2-glycoprotein-I antibodies 
 PE: phosphatidylethanolamine 
aPE: anti-phosphatidylethanolamine antibodies 
 GAPSS: global APS score 
aPS/PT: anti-phosphatidylserine/prothrombin complex antibodies 
 aPT: anti-prothrombin antibodies 
aAnxA5: anti-AnxA5 antibodies 
 APC: activated protein C 
 dRVVT: diluted Russell viper venom time 
aPTT: activated partial thromboplastin time 
 PE: pulmonary embolism 
 DVT: deep vein thrombosis 
TIA: transient ischemic attacks 
 MTC: mixing test-specific cut-off 
 ICA: index of circulating anticoagulant 
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Table 1 APS classification criteria, modified from Miyakis et al. [5] 
 
Vascular 
thrombosis: 
 
≥1 Clinical episode of arterial, venous or small vessel thrombosis. Thrombosis must be 
objectively confirmed. For histopathological confirmation, thrombosis must be present without 
inflammation of the vessel wall 
Pregnancy 
morbidity: 
1. ≥1 Unexplained death of a morphologically normal fetus ≥10 weeks of gestation 
2. ≥1 Premature delivery of a morphologically normal fetus <34 weeks gestation because of: 
   Severe pre-eclampsia or eclampsia defined according to standard definition 
   Recognised features of placental insufficiency 
3. ≥3 Unexplained consecutive miscarriages <10 weeks gestation, with maternal and paternal 
factors (anatomic, hormonal or chromosomal abnormalities) excluded 
Laboratory 
criteria: 
The presence of antiphospholipid antibodies (aPL), on two or more occasions at least 12 weeks 
apart and no more than 5 years prior to clinical manifestations, as demonstrated by ≥1 of the 
following 
   Presence of lupus anticoagulant in plasma 
   Medium to high-titre anticardiolipin antibodies (>40 GPL or MPL, or >99th ‰) of IgG or 
IgM isoforms 
   Anti-β2 glycoprotein-I antibody (anti-β2GPI) of IgG or IgM present in plasma 
 
 
 
 
Table 2 The global antiphospholipid syndrome score (GAPSS) 
 
 
Factor 
Point valuea 
aPLa Anticardiolipin IgG/IgM 5 
  Anti-β2-glycoprotein IgG/IgM 4 
  Lupus anticoagulant 4 
  Anti-prothrombin/phosphatidylserine complex (aPS/PT) IgG/IgM 3 
Cardiovascular risk factors Hyperlipidemiab 3 
  Arterial hypertensionc 1 
 
 
Cardiovascular risk factors were assessed following National Institute for Health and Clinical Excellence 
guidelines (Excellence NIfHaC. Lipid modification: cardiovascular risk assessment and the modification of blood 
lipids for the primary and secondary prevention of cardiovascular disease. 2010. 
URL: http://www.nice.org.uk/guidance/CG181 and Excellence NIfHaC. Hypertension. 2011. 
URL: http://www.nice.org.uk/guidance/QS28) 
aaPL positivity was assessed according to the updated APS classification criteria [5] 
bSerum total and high-density lipoprotein cholesterol levels were determined with standardized enzymatic 
methods and interpreted according to current cutoff values (total cholesterol of <5.0 mmol/l; <3.0 mmol/l for low-
density lipoprotein cholesterol) (British Cardiac Society, British Hypertension Society, Diabetes UK, HEART 
UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies’ guidelines on 
prevention of cardiovascular disease in clinical practice. Heart 2005; Suppl 5:v1–52) 
cArterial hypertension was defined as appropriately sized high blood pressure cutoff (140/90 mm Hg or higher) at 
least in two occasions or use of oral antihypertensive medications 
 
